News for Nkarta, Inc. (NKTX)

**media[591526,591527]**

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth PALO ALTO, Calif., April 04, 2025 (GLOBE NEW

**media[582715]**

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more about NKTX stock here.

New Jersey-based Greenland Acquisition Corp (GTEC) is up over 79 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Morning Reads

**media[577728]**

The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. ( NKTX), a biopharmaceutical company developing engineered natural killer (NK) cel

On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a substantial reduction in its holdings of Nkarta Inc (NKTX). The firm decreased its pos

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple opportunities despite market risks.

On December 6, 2024, Citadel Advisors LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 680,632 shares of Nkarta Inc (NKTX) a

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (I

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. ( NKTX), a biopharmaceutical company developing engineered natural killer (NK) cel

**media[463410]**

Nkarta is working on engineered NK cell therapies for autoimmune diseases and cancer. Click here to find out why I maintain a hold sentiment on NKTX stock.

Nkarta faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning chemotherapy. See why NKTX stock is a Hold.

The most oversold stocks in the health care sector present an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When ...